Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Ltd
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
To demonstrate the superiority of triple therapy, casopitant, ZOFRAN and dexamethasone over dual therapy, ZOFRAN and dexamethasone in the prevention of emesis over the first 120 hours following the in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder
To evaluate the antidepressant efficacy of GSK372475 compared to placebo in subjects diagnosed with MDD with symptoms of decreased pleasure, interest and energy as measured by the Inventory of Depress...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study of eltrombopag in combination with azacitidine for subjects with low platelet counts due to intermediate 1, intermediate 2 or high risk Myelodysplastic Syndromes (MDS)
The primary objective of this study is to determine the effect of eltrombopag versus placebo on the proportion of subjects who are platelet transfusion free during the first 4 cycles of azacitidine th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder 200mcg Once-Daily, and GW685698X Inhalation Powder 400mcg Once-Daily in the Morning Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy
To evaluate the relative efficacy and safety of GW685698X 200mcg twice daily and GW685698X 400mcg once daily in the morning compared with placebo in adolescent and adult subjects with persistent asthm...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A clinical study to investigate the pharmacokinetics safety, and tolerability of a single dose of GSK2402968 in non-ambulant subjects with Duchenne muscular dystrophy (GSK Study Number DMD114118)
To assess the PK, safety and tolerability of GSK2402968 after a single subcutaneous administration at different dose levels in non-ambulatory subjects with Duchenne muscular dystrophy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Efficacy and safety study for Fluticasone Furoate Nasal Spray in adults and adolescents with non-allergic rhinitis
To compare the efficacy and safety of fluticasone furoate nasal spray 110 mcg (FFNS) once daily with placebo nasal spray in subjects with irritant (non-allergic) rhinitis triggered predominantly by ai...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A 12-week study to test lung function in people with COPD and who have or at risk for cardiovascular disease
The primary objective of this study is to evaluate the efficacy (particularly the change from baseline trough in 24-hour weighted-mean serial FEV1 at the end of a 12-week treatment period) and safety ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to assess the effect of rilapladib (SB 659032) on Alzheimer’s disease
To examine in an exploratory manner whether rilapladib produces changes in CSF biomarkers that are consistent with effects on increased CNS Aβ clearance in AD patients and whether these findings are a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7